Perrigo (PRGO) Other Non-Current Assets (2013 - 2026)
Perrigo (PRGO) reported Other Non-Current Assets of $260.5 million for Q1 2026, up 1068.16% year-over-year from $22.3 million in Q1 2025, and little changed quarter-over-quarter from $261.8 million in Q4 2025.
Perrigo (PRGO) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Other Non-Current Assets data on file, last reported at $260.5 million in Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $260.5 million, up 1068.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $260.5 million (up 1068.16% YoY), and the FY2025 annual result was $261.8 million, down 17.83% from the prior year.
- Other Non-Current Assets was little changed at $260.5 million in Q1 2026 per PRGO's latest filing, from $261.8 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $408.6 million in Q3 2022 and troughed at $22.3 million in Q1 2025.
- A 5-year average of $312.3 million and a median of $326.9 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets sank 93.62% in 2025, then soared 1068.16% in 2026.
- A 5-year view of Other Non-Current Assets shows it stood at $367.7 million in 2022, then fell by 8.84% to $335.2 million in 2023, then decreased by 4.95% to $318.6 million in 2024, then fell by 17.83% to $261.8 million in 2025, then declined by 0.5% to $260.5 million in 2026.
- Business Quant data shows PRGO's Other Non-Current Assets at $260.5 million in Q1 2026, $261.8 million in Q4 2025, and $301.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 1.79 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 351.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 233.20 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 3.45 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 73.60 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 295.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 59.36 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 47.63 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | - |
| 10 | Perrigo | 1.55 Bn | 1.19 Bn | 325.50 Mn | 260.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 260.50 Mn |
| Dec 31, 2025 | 261.80 Mn |
| Sep 27, 2025 | 301.80 Mn |
| Jun 28, 2025 | 301.60 Mn |
| Mar 29, 2025 | 22.30 Mn |
| Dec 31, 2024 | 318.60 Mn |
| Sep 28, 2024 | 299.50 Mn |
| Jun 29, 2024 | 292.30 Mn |
| Mar 30, 2024 | 349.40 Mn |
| Dec 31, 2023 | 335.20 Mn |
| Sep 30, 2023 | 387.30 Mn |
| Jul 1, 2023 | 371.60 Mn |
| Apr 1, 2023 | 342.80 Mn |
| Dec 31, 2022 | 367.70 Mn |
| Jul 2, 2022 | 408.60 Mn |
| Apr 2, 2022 | 375.70 Mn |
| Dec 31, 2021 | 377.50 Mn |
| Oct 2, 2021 | 373.30 Mn |
| Jul 3, 2021 | 2.09 Bn |
| Apr 3, 2021 | 343.60 Mn |